Clinical trial
ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)
NCT00313560 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00313560 |
|---|---|
| Title | ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA) |
| Official title | Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Enrollment | 48 |
| Start date | Mar 16, 2006 |
| Primary completion | Dec 27, 2013 |
| Completion | Feb 27, 2019 |
| First posted | Apr 12, 2006 |
| Last update posted | Jun 4, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: